John Breton

1.7k total citations · 1 hit paper
35 papers, 889 citations indexed

About

John Breton is a scholar working on Pharmacology, Molecular Biology and Immunology. According to data from OpenAlex, John Breton has authored 35 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 10 papers in Molecular Biology and 9 papers in Immunology. Recurrent topics in John Breton's work include Inflammatory mediators and NSAID effects (8 papers), Urinary Tract Infections Management (5 papers) and Natural product bioactivities and synthesis (4 papers). John Breton is often cited by papers focused on Inflammatory mediators and NSAID effects (8 papers), Urinary Tract Infections Management (5 papers) and Natural product bioactivities and synthesis (4 papers). John Breton collaborates with scholars based in United States, United Kingdom and Colombia. John Breton's co-authors include Marie Chabot‐Fletcher, Don E. Griswold, Jerry L. Adams, John C. Lee, Margaret E. Sorenson, Ravi S. Garigipati, Edward F. Webb, Timothy F. Gallagher, Jeffrey T. Laydon and C. Jacques and has published in prestigious journals such as The Lancet, Scientific Reports and Biochemical Journal.

In The Last Decade

John Breton

33 papers receiving 846 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials

2024 44 citations Florian Wagenlehner, Caroline Perry et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Breton United States	17	360	234	144	115	113	35	889
Mi Jeong Kim South Korea	20	471 1.3×	134 0.6×	76 0.5×	265 2.3×	108 1.0×	62	1.4k
Anton Stuetz Austria	23	289 0.8×	242 1.0×	64 0.4×	328 2.9×	101 0.9×	35	1.5k
David W. A. Beno United States	21	491 1.4×	159 0.7×	56 0.4×	186 1.6×	161 1.4×	54	1.4k
Denis Thiolat France	16	332 0.9×	336 1.4×	57 0.4×	343 3.0×	148 1.3×	19	1.3k
Maria Rybczyńska Poland	20	603 1.7×	86 0.4×	51 0.4×	147 1.3×	155 1.4×	63	1.1k
Koraljka Gall‐Trošelj Croatia	19	478 1.3×	150 0.6×	35 0.2×	54 0.5×	104 0.9×	54	1.0k
Holger Ulbrich Germany	15	241 0.7×	199 0.9×	139 1.0×	239 2.1×	78 0.7×	19	843
Hiroshi Azuma Japan	14	394 1.1×	77 0.3×	111 0.8×	377 3.3×	89 0.8×	40	1.2k
Tomoyuki Kitazaki Japan	16	343 1.0×	260 1.1×	63 0.4×	525 4.6×	69 0.6×	33	1.3k

Countries citing papers authored by John Breton

Since Specialization

Citations

This map shows the geographic impact of John Breton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Breton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Breton more than expected).

Fields of papers citing papers by John Breton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Breton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Breton. The network helps show where John Breton may publish in the future.

Co-authorship network of co-authors of John Breton

This figure shows the co-authorship network connecting the top 25 collaborators of John Breton. A scholar is included among the top collaborators of John Breton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Breton. John Breton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scangarella-Oman, Nicole E., John Breton, D. J. Brown, et al.. (2025). Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). Antimicrobial Agents and Chemotherapy. 69(10). e0164024–e0164024. 1 indexed citations

Scangarella-Oman, Nicole E., et al.. (2025). Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes/epidemiological clones, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). Antimicrobial Agents and Chemotherapy. 69(10). e0163924–e0163924.

Wagenlehner, Flo ri an, Caroline Perry, Thomas M. Hooton, et al.. (2024). Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. The Lancet. 403(10428). 741–755. 44 indexed citations breakdown →

Wagenlehner, Flo ri an, Caroline Perry, Thomas M. Hooton, et al.. (2023). P31 Efficacy and safety of oral gepotidacin in the treatment of uncomplicated urinary tract infection: results of two randomized, multicentre Phase 3 trials (EAGLE-2 and EAGLE-3). JAC-Antimicrobial Resistance. 5(Supplement_3). 2 indexed citations

Jacques, C., L. Sudre, John Breton, et al.. (2022). Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?. Journal of Orthopaedic Translation. 32. 121–129. 47 indexed citations

Sudre, L., John Breton, Carole Bougault, et al.. (2022). Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Scientific Reports. 12(1). 1567–1567. 78 indexed citations

Vélez, Iván Darío, Tran Tinh Hien, Justin A. Green, et al.. (2021). Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial. The Lancet Child & Adolescent Health. 6(2). 86–95. 7 indexed citations

Tanus, Tonny, et al.. (2014). A Randomized, Double-blind, Comparative Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment 1% Versus Oral Linezolid in the Treatment of Secondarily Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus. Advances in Skin & Wound Care. 27(12). 548–559. 9 indexed citations

Tomayko, John, et al.. (2013). The Safety and Efficacy of Topical Retapamulin Ointment Versus Placebo Ointment in the Treatment of Secondarily Infected Traumatic Lesions. Advances in Skin & Wound Care. 26(3). 113–121. 6 indexed citations

10.

Anon, Jack B., Elchonon M. Berkowitz, John Breton, & Monique Twynholm. (2006). Efficacy/safety of amoxicillin/clavulanate in adults with bacterial rhinosinusitis. American Journal of Otolaryngology. 27(4). 248–254. 5 indexed citations

11.

Parish, Lawrence Charles, et al.. (2006). Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: Results of a randomized controlled trial. Journal of the American Academy of Dermatology. 55(6). 1003–1013. 43 indexed citations

12.

Sarau, Henry M., James J. Foley, Dulcie B. Schmidt, et al.. (1999). In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4receptor antagonist with anti-inflammatory activity. Prostaglandins Leukotrienes and Essential Fatty Acids. 61(1). 55–64. 6 indexed citations

13.

Griswold, Don E., et al.. (1998). Evaluation of the cutaneous anti-inflammatory activity of azaspiranes. Inflammation Research. 47(2). 56–61. 17 indexed citations

14.

Chabot‐Fletcher, Marie & John Breton. (1998). Effect of Staurosporine on Transcription Factor NF-κB in Human Keratinocytes. Biochemical Pharmacology. 56(1). 71–78. 10 indexed citations

15.

Breton, John & Marie Chabot‐Fletcher. (1997). The Natural Product Hymenialdisine Inhibits Interleukin-8 Production in U937 Cells by Inhibition of Nuclear Factor-κB. Journal of Pharmacology and Experimental Therapeutics. 282(1). 459–466. 21 indexed citations

16.

Breton, John, Deborah J. Woolf, Peter R. Young, & Marie Chabot‐Fletcher. (1996). Human Keratinocytes Lack the Components to Produce Leukotriene B4. Journal of Investigative Dermatology. 106(1). 162–167. 20 indexed citations

17.

Chabot‐Fletcher, Marie, et al.. (1994). Human Keratinocytes Possess an sn-2 Acylhydrolase that is Biochemically Similar to the U937-Derived 85-kDa Phospholipase A2. Journal of Investigative Dermatology. 102(6). 980–986. 17 indexed citations

18.

Chabot‐Fletcher, Marie, et al.. (1994). Interleukin-8 Production Is Regulated by Protein Kinase C in Human Keratinocytes. Journal of Investigative Dermatology. 103(4). 509–515. 38 indexed citations

19.

Breton, John, Paul M. Keller, Marie Chabot‐Fletcher, et al.. (1993). Use of a continous assay of oxygen consumption to evaluate the pharmacology of 5-lipoxygenase inhibitors. Prostaglandins Leukotrienes and Essential Fatty Acids. 49(6). 929–937. 9 indexed citations

20.

Griswold, Don E., Edward F. Webb, John Breton, et al.. (1993). Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation. 17(3). 333–344. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact